Johnson Matthey PLC (LON:JMAT - Get Free Report)'s stock price shot up 29.9% during mid-day trading on Thursday . The company traded as high as GBX 1,888 ($25.62) and last traded at GBX 1,804 ($24.48). 3,118,679 shares changed hands during trading, an increase of 14% from the average session volume of 2,740,734 shares. The stock had previously closed at GBX 1,389 ($18.85).
Johnson Matthey Trading Down 1.5%
The stock's 50-day simple moving average is GBX 1,313.40 and its two-hundred day simple moving average is GBX 1,377.22. The company has a debt-to-equity ratio of 62.73, a current ratio of 1.45 and a quick ratio of 0.76. The firm has a market capitalization of £2.85 billion, a P/E ratio of 28.96, a price-to-earnings-growth ratio of 49,242.50 and a beta of 0.95.
Johnson Matthey (LON:JMAT - Get Free Report) last issued its earnings results on Thursday, May 22nd. The company reported GBX 149.20 ($2.02) earnings per share (EPS) for the quarter. Johnson Matthey had a return on equity of 4.49% and a net margin of 0.84%. Equities research analysts expect that Johnson Matthey PLC will post 173.4112903 EPS for the current year.
Johnson Matthey Increases Dividend
The business also recently declared a dividend, which was paid on Wednesday, April 16th. Shareholders of record on Thursday, April 10th were issued a GBX 32 ($0.43) dividend. This is an increase from Johnson Matthey's previous dividend of $22.00. This represents a yield of 1.88%. The ex-dividend date was Thursday, April 10th. Johnson Matthey's payout ratio is currently 130.84%.
Insiders Place Their Bets
In related news, insider Liam Condon acquired 30 shares of Johnson Matthey stock in a transaction on Wednesday, April 16th. The shares were bought at an average cost of GBX 1,200 ($16.28) per share, with a total value of £360 ($488.47). Insiders have purchased a total of 75 shares of company stock worth $99,927 in the last 90 days. 0.61% of the stock is currently owned by corporate insiders.
Johnson Matthey Company Profile
(
Get Free Report)
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers' products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet's natural resources.
Featured Articles
Before you consider Johnson Matthey, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson Matthey wasn't on the list.
While Johnson Matthey currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.